Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141


Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.

Fluge Ø, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, Næss H, Dahl O, Nyland H, Mella O.

PLoS One. 2011;6(10):e26358. doi: 10.1371/journal.pone.0026358. Epub 2011 Oct 19.


B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.

Fluge Ø, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D, Kristoffersen EK, Sørland K, Bruland O, Dahl O, Mella O.

PLoS One. 2015 Jul 1;10(7):e0129898. doi: 10.1371/journal.pone.0129898. eCollection 2015.


Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.

Lunde S, Kristoffersen EK, Sapkota D, Risa K, Dahl O, Bruland O, Mella O, Fluge Ø.

PLoS One. 2016 Aug 18;11(8):e0161226. doi: 10.1371/journal.pone.0161226. eCollection 2016.


Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study.

Mensah F, Bansal A, Berkovitz S, Sharma A, Reddy V, Leandro MJ, Cambridge G.

Clin Exp Immunol. 2016 May;184(2):237-47. doi: 10.1111/cei.12749. Epub 2016 Feb 22.


Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis.

Leiper K, Martin K, Ellis A, Subramanian S, Watson AJ, Christmas SE, Howarth D, Campbell F, Rhodes JM.

Gut. 2011 Nov;60(11):1520-6. doi: 10.1136/gut.2010.225482. Epub 2011 Apr 6.


Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; REFLEX Trial Group.

Arthritis Rheum. 2006 Sep;54(9):2793-806.


Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.

Salvi M, Vannucchi G, Campi I, Currò N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P.

Eur J Endocrinol. 2007 Jan;156(1):33-40.


Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.

Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H.

Arthritis Rheum. 2010 Apr;62(4):960-8. doi: 10.1002/art.27314.


B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.

Myers RP, Swain MG, Lee SS, Shaheen AA, Burak KW.

Am J Gastroenterol. 2013 Jun;108(6):933-41. doi: 10.1038/ajg.2013.51. Epub 2013 May 7.


Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).

Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, Roué IQ, Cochener B, Youinou P, Saraux A.

Arthritis Rheum. 2007 Mar 15;57(2):310-7.


Rituximab for thyroid eye disease.

Silkiss RZ, Reier A, Coleman M, Lauer SA.

Ophthalmic Plast Reconstr Surg. 2010 Sep-Oct;26(5):310-4. doi: 10.1097/IOP.0b013e3181c4dfde.


Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial.

Roerink ME, Knoop H, Bredie SJ, Heijnen M, Joosten LA, Netea MG, Dinarello CA, van der Meer JW.

Trials. 2015 Oct 5;16:439. doi: 10.1186/s13063-015-0971-z.


A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation.

Tydén G, Genberg H, Tollemar J, Ekberg H, Persson NH, Tufveson G, Wadström J, Gäbel M, Mjörnstedt L.

Transplantation. 2009 May 15;87(9):1325-9. doi: 10.1097/TP.0b013e3181a235fd.


Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.

Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y; Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group.

Lancet. 2014 Oct 4;384(9950):1273-81. doi: 10.1016/S0140-6736(14)60541-9. Epub 2014 Jun 22.


A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.

Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, Lapp CW, Peterson DL; Chronic Fatigue Syndrome AMP-516 Study Group, Mitchell WM.

PLoS One. 2012;7(3):e31334. doi: 10.1371/journal.pone.0031334. Epub 2012 Mar 14.


Effective B cell depletion with rituximab in the treatment of autoimmune diseases.

Kneitz C, Wilhelm M, Tony HP.

Immunobiology. 2002 Dec;206(5):519-27.


Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.

Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, Lee ST, de Saint Sardos A, Butler NJ, Smith JR, Rosenbaum JT.

JAMA Ophthalmol. 2014 May;132(5):572-8.


Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.

Hassan R, Williams-Gould J, Watson T, Pai-Scherf L, Pastan I.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):16-8.


A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome.

McDermott C, Richards SC, Thomas PW, Montgomery J, Lewith G.

QJM. 2006 Jul;99(7):461-8. Epub 2006 Jun 29.


Supplemental Content

Support Center